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Taylor et al.1 concluded that in Mohs Micrographic Surgery the risk of bleeding is very low 40 
and advocate staying on blood-thinning medications.1 This is encouraging, however, 41 
complications arising from the documented bleeding events including skin graft failure and 42 
secondary infection, were not stated. This is important to know for the procedure outcome.  43 
We propose a patient-centred approach when considering continuing or withholding blood-44 
thinning medications during cutaneous surgery, taking into account the risk:benefit ratio of 45 
the medication and surgery. A fictional case will demonstrate this:    46 
A 66-year-old diabetic female with atrial fibrillation, on a direct oral anticoagulant (DOAC) 47 
for stroke prevention, is due to have a 4cm squamous cell carcinoma on her scalp excised to 48 
the periosteum with a split-thickness skin graft repair. 49 
The bleeding risk should be balanced against the risk of withholding the DOAC. 50 
CHA(2)DS(2)-VASc score predicts the risk of stroke,2 and this patient scores  3 (sex, age and 51 
diabetes mellitus) which equates to a risk of 37 per 1000 people in one year having a stroke if 52 
not anticoagulated.3 Therefore, this patient’s risk of stroke on one day if not anticoagulated is 53 
estimated as 1 in 9865 ((37/1000)/365); although surgery-associated stress may  increase this 54 
risk. The bleeding risk should be reviewed by assessing patient risk factors and their 55 
anticoagulant medication. A dermatologist cannot assume what is an acceptable risk to a 56 
patient nor presume to tell a patient to stop medications without a risk:benefit discussion; 57 
quantifying the risks may help. In the UK the Montgomery judgement conveys this concept 58 
and is a legal principle in informed consent.4 I  ruled that doctors have “a duty to take 59 
reasonable care to ensure that the patient is aware of ny material risks involved”.4  60 
Careful consideration of blood-thinners should be giv n in other complex reconstructions eg. 61 
paramedian flap repair, local skin flaps, hard to compress sites eg. periocular, where 62 










requires a longer cessation period (5-10 days) compared to DOACs (24-48 hours) to 64 
normalise coagulation and once restarted takes longer to achieve therapeutic anticoagulation, 65 
therefore it has an increased risk of thromboembolism on cessation compared to DOACs. 66 
Nuanced strategies may be considered; egs. swapping clopidogrel for aspirin as it is 67 
associated with less bleeding, performing surgery at the DOAC trough level, stopping one of 68 
two blood-thinning medications or adjusting the medication so that it has reduced but not 69 
zero efficacy. The patient’s cardiologist or primary care physician should be consulted if 70 
modification is required. 71 
The American College of Cardiology recommends performing procedures with uninterrupted 72 
anticoagulation when there is ‘no clinically importan  bleeding risk’5 which we suggest would 73 
be most dermatologic surgery. It may never be appropriate to stop blood-thinning medications 74 
in patients with coronary drug-eluting stents or valvular heart disease. However, there is a 75 
case for withholding/adjusting these medications when the risk:benefit ratio is favourable eg. 76 
individuals with a low risk of a vascular event undergoing complex skin surgery.  We 77 
emphasise undertaking individual patient assessments and involving patients in the decision. 78 
 79 
References 80 
1. Taylor O, Carr C, Greif C, Garcia A, Tran S, Srivastava D, Nijhawan RI. 81 
Postoperative Bleeding Complications Associated with Blood Thinning Agents during 82 
Mohs Micrographic Surgery: A Retrospective Cohort Study. Journal of the American 83 
Academy of Dermatology 2020; doi: https://doi.org/10.1016/j.jaad.2020.06.011 84 
2. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining Clinical Risk 85 









a Novel Risk Factor-Based Approach: The Euro Heart Su vey on Atrial Fibrillation. 87 
Chest 2010;137(2):263-272.  88 
3. National Institute for health and care excellence (NICE). Atrial fibrillation: medicines 89 
to help reduce your risk of a stroke – what are the options? Patient decision aid.  90 
NICE, 2014. Available from: 91 
https://www.nice.org.uk/guidance/cg180/resources/cg180-atrial-fibrillation-update-92 
patient-decision-aid-243734797 [accessed 28/06/2020]. 93 
4. Montgomery v Lanarkshire Health Board [2015] UKSC 11, paragraph 87. Available 94 
from: 95 
https://www.supremecourt.uk/cases/docs/uksc-2013-0136-judgment.pdf [accessed 96 
28/06/2020]. 97 
5. Doherty JU, Gluckman TJ, Hucker WJ et al. 2017 ACC Expert Consensus Decision 98 
Pathway for Periprocedural Management of Anticoagultion in Patients With 99 
Nonvalvular Atrial Fibrillation: A Report of the American College of Cardiology 100 



















Taylor et al.1 concluded that in Mohs Micrographic Surgery the risk of bleeding is very low 111 
and advocate staying on  blood-thinning medications.1 This is encouraging, however, 112 
complications arising from the documented bleeding events including skin graft failure and 113 
secondary infection, were not stated. This is important to know for the procedure outcome.  114 
We propose a patient-centred approach when considering continuing or withholding blood-115 
thinning medications during cutaneous surgery, taking into account the risk:benefit ratio of 116 
the medication and surgery. A fictional case will demonstrate this:    117 
A 66-year-old diabetic female with atrial fibrillation, on a direct oral anticoagulant (DOAC) 118 
for stroke prevention, is due to have a 4cm squamous cell carcinoma on her scalp excised to 119 
the periosteum with a split-thickness skin graft repair. 120 
The bleeding risk should be balanced against the risk of withholding the DOAC. 121 
CHA(2)DS(2)-VASc score predicts the risk of stroke,2 and this patient scores  3 (sex, age and 122 
diabetes mellitus) which equates to a risk of 37 per 1000 people in one year having a stroke if 123 
not anticoagulated.3 Therefore, this patient’s risk of stroke on one day if not anticoagulated is 124 
estimated as 1 in 9865 ((37/1000)/365); although surgery-associated stress may  increase this 125 
risk. The bleeding risk should be reviewed by assessing patient risk factors and their 126 
anticoagulant medication. A dermatologist cannot assume what is an acceptable risk to a 127 
patient nor presume to tell a patient to stop medications without a risk:benefit discussion; 128 
quantifying the risks may help. In the UK the Montgomery judgement conveys this concept 129 
and is a legal principle in informed consent.4 I  ruled that doctors have “a duty to take 130 
reasonable care to ensure that the patient is aware of ny material risks involved”.4  131 
Careful consideration of blood-thinners should be giv n in other complex reconstructions eg. 132 










excessive bleeding can be problematic. The anticoagulant should be considered. Warfarin 134 
requires a longer cessation period (5-10 days) compared to DOACs (24-48 hours) to 135 
normalise coagulation and once restarted takes longer to achieve therapeutic anticoagulation, 136 
therefore it has an increased risk of thromboembolism on cessation compared to DOACs. 137 
Nuanced strategies may be considered; egs. swapping clopidogrel for aspirin as it is 138 
associated with less bleeding, performing surgery at the DOAC trough level, stopping one of 139 
two blood-thinning medications or adjusting the medication so that it has reduced but not 140 
zero efficacy. The patient’s cardiologist or primary care physician should be consulted if 141 
modification is required. 142 
The American College of Cardiology recommends performing procedures with uninterrupted 143 
anticoagulation when there is ‘no clinically importan  bleeding risk’5 which we suggest would 144 
be most dermatologic surgery. It may never be appropriate to stop blood-thinning medications 145 
in patients with coronary drug-eluting stents or valvular heart disease. However, there is a 146 
case for withholding/adjusting these medications when the risk:benefit ratio is favourable eg. 147 
individuals with a low risk of a vascular event undergoing complex skin surgery.  We 148 
emphasise undertaking individual patient assessments and involving patients in the decision. 149 
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